SYRS (Syros Pharmaceuticals Inc.) Return on Gross Profit

Corporate emblem and logo of Syros Pharmaceuticals Inc. (SYRS)

Syros Pharmaceuticals (SYRS) is optimizing raw material supply chains for DNA therapy to ensure high operational resilience. Business development relies on venture investments and the success of clinical hypotheses. The portfolio includes leukemia treatments with a projected market entry by 2026. The value of 0.00 determines the current parameter status, which clearly demonstrates the distribution of gross margin.

Return on Gross Profit: Syros Pharmaceuticals (SYRS) for 07/04/2022 - 03/29/2025

Financial and market metric breakdowns for syros.com (SYRS)

Fundamental valuation:SYRS, Syros Pharmaceuticals, Inc.
Flagship merchandise of Syros Pharmaceuticals

For Syros Pharmaceuticals (SYRS), which is currently in the active development stage of hematology drugs, gross margin serves as a key indicator of direct cost management efficiency. By analyzing this gross profitability chart, an investor can see the portion of revenue remaining after deducting the cost of goods sold. The stability of this metric confirms the company's ability to monetize innovations in gene expression upon its market entry in 2026.

Direct competitors

Return on Gross Profit Tempus AI Inc|QGEN (Qiagen NV) - Gross Margin|Return on Gross Profit Ionis Pharma (IONS)|Gross Profitability Repligen Corp (RGEN)|RNA - Gross Profit Margin|crisprtx.com - Return on Gross Profit|Gross Profit Rate WGS|RARE - Gross Profitability|Beam Tx (BEAM) - Return on Gross Profit|SRPT (Sarepta Therapeutics Inc) - Return on Gross Profit|TWST: Gross Profit Ratio|TXG (10xgenomics.com) - Gross Margin|NTLA (Intellia Therapeutics, Inc.) - Gross Profit Ratio|Gross Profitability Stoke Corp (STOK)|Return on Sales by Gross Profit BioLife|Gross Margin WVE (Wave Life Sciences Ltd)|MAZE: Gross Return on Sales|Sionna Therapeutics, Inc. - Gross Margin|Gross Profit Rate PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Return on Gross Profit|QURE - Return on Sales by Gross Profit|MGTX (MeiraGTx Corp) - Gross Margin|Gross Profit Margin REGENXBIO Inc. RGNX|Gross Profitability Solid Biosciences (SLDB)|Ocugen Corp - Gross Return on Sales|Gross Profitability Pacific Biosciences PACB|Gross Profit Ratio BNTC (Benitec)|Design Corp - Gross Margin|Rocket Pharmaceuticals - Gross Profit Ratio|Gross Return on Sales 4D Molecular Therapeutics, Inc.|Gross Profit Margin Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Gross Margin|Gross Profit Margin Editas EDIT|Gross Margin SLN|ProQR Therapeutics - Gross Return on Sales|Gross Margin CDXS (Codexis, Inc.)|SGMO: Gross Return on Sales|Nautilus Biotechnology - Gross Margin|Gross Profit Rate MGX (Metagenomi, Inc)|DTIL: Gross Margin|GBIO: Gross Profit Ratio|Gross Profitability Boundless Bio Inc.|Return on Gross Profit Exicure (XCUR)|Gross Margin IMNN|PHIO (Phio Pharmaceuticals Corp.) - Gross Profit Rate|Mustang Bio, Inc. - Return on Gross Profit|RNAZ - Return on Gross Profit|BNGO: Return on Gross Profit|APDN (Applied DNA Sciences Inc) - Gross Return on Sales|BLUE (Bluebird Bio) - Return on Gross Profit|ImmunoPrecise Antibodies Ltd - Gross Profit Rate|OMGA (Omega Therapeutics Inc) - Gross Margin|Gross Profitability OMIC|Gross Profitability Regulus Therapeutics Inc. (RGLS)|Return on Sales by Gross Profit Codex DNA|Gross Profitability TRACON TCON|Unity Biotechnology, Inc - Gross Profitability